spacer
home > epc > spring 2002 > why it is worth conducting clinical trials in poland
PUBLICATIONS
European Pharmaceutical Contractor

Why it is Worth Conducting Clinical Trials in Poland

Since the end of the 1980s clinical studies have been conducted in all Central and Eastern European (CEE) countries according to GCP standards. The growth of registered trials continues today (see Figures 1-4).

It may seem that this was the main factor encouraging Western companies to start trials in Poland. Yet it is more complicated than that. By taking a closer look it is evident that there are many other advantages to performing trials in the region. This article will try and address the following questions: "Why are pharmaceutical companies taking their clinical research to CEE countries?" and "Why do they come to countries like Poland?" We will try to answer the questions in the article by placing Poland in the context of other CEE countries and the rest of Europe.

What are the Main Advantages of Conducting Clinical Research in Poland?

The first factor to consider is population. The CEE population stands at more than 153 million in total. Thirty-eight million of those live in Poland. This makes Poland the second most populous place in the region (see Figure 5). This prolific population creates a very good availability of patients. This wide availability of patients is the most important factor driving pharmaceutical companies to Poland and other CEE countries. Table 1 lists the most sought after populations.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Marcin Dudek, Director of Clinical Operations at Kiecana and Dr Aneta Sitarska-Haber, Clinical Research Manager

Dr Marcin Dudek is Director of Clinical Operations at Kiecana Clinical Research. He received his Medical Diploma at Warsaw Medical Academy in 1994 before undertaking one year's postgraduate training at the Cardiology Department of Brуdnowski Hospital in Warsaw. In 1995 he decided to join the pharmaceutical industry. He began his career in the Polish branch of Pharmakopius International, as a CRA focusing on cardiological studies. Following changes within the Polish office he was appointed Clinical Trials Manager, and was responsible for the clinical operations of the company in Poland. In 1998 he joined Kiecana Clinical Research.

Dr Aneta Sitarska-Haber has had a short but very intensive experience in clinical research. She received her Medical Diploma at Warsaw Medical Academy in 1997 and underwent one year's postgraduate training at the Teaching Hospital in Warsaw.

She started her career as a CRA at the beginning of 1999 at Kiecana Clinical Research, and since then has been involved in many clinical studies at all phases. Her current position within KCR is Clinical Research Manager


spacer
Dr Marcin Dudek
spacer
spacer
spacer
Dr Aneta Sitarska-Habe
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health finds growing eConsent adoption forecasts and the importance of eClinical integration in latest “State of eConsent” survey

PHILADELPHIA, PA – January 16, 2020: Signant Health, released the findings from its latest “State of eConsent” report today, highlighting the sentiments, successes, and challenges of eConsent practitioners around the world. Join Signant Health’s webinar on February 12, 2020 at 11am ET or 3pm ET to learn more about the findings.
More info >>

White Papers

EU GDP Guidelines: Implications for Shipping Clinical Materials into the European Market

PCI Pharma Services

Recently, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) opened an investigation into a patient complaint of mold on paracetamol (acetaminophen) tablets (1). It discovered the product was shipped by sea from India to multiple companies in the UK at temperatures reaching up to 60 degrees Celsius. Labeling for paracetamol tablets typically states they should be kept below 30 degrees Celsius. In addition, MHRA discovered the humidity levels exceeded 80 percent during shipping, which is too high for the packaging that was used.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement